

**Table 3. Performance of top four markers in samples based on gender, race/ethnicity and stage.**

	Median PMR		p-value <sup>a</sup>
	T	Adj NTL	
<b>GENDER</b>			
<b>Male</b>	(n=28)	(n=19)	
CDKN2A EX2	199.44	51.88	5.0E-06
CDX2	28.40	4.78	2.0E-05
HOXA1	139.51	5.06	4.6E-05
OPCML	76.62	11.27	1.6E-06
<b>Female</b>	(n=14)	(n=10)	
CDKN2A EX2	189.16	38.64	1.3E-04
CDX2	114.71	3.15	4.0E-05
HOXA1	188.13	1.34	3.1E-06
OPCML	154.32	5.36	3.1E-06
<b>RACE</b>			
<b>White Hispanic</b>	(n=14)	(n=10)	
CDKN2A EX2	165.47	37.52	6.0E-04
CDX2	39.49	1.98	2.0E-04
HOXA1	52.98	1.75	7.7E-03
OPCML	142.56	8.17	6.0E-04
<b>White Non-Hispanic</b>	(n=14)	(n=10)	
CDKN2A EX2	314.35	38.00	5.0E-04
CDX2	110.73	4.78	1.1E-03
HOXA1	231.66	4.90	4.6E-05
OPCML	179.79	6.54	4.7E-05
<b>Black</b>	(n=11)	(n=7)	
CDKN2A EX2	194.91	51.88	1.5E-02
CDX2	129.96	9.11	2.4E-02
HOXA1	128.52	6.16	1.1E-02
OPCML	91.15	14.29	5.0E-03
<b>Asian</b>	(n=6)	(n=4)	
CDKN2A EX2	145.56	39.81	<b>1.1E-01</b>
CDX2	24.28	1.78	2.3E-02
HOXA1	117.49	0.99	1.4E-02
OPCML	88.81	4.67	1.4E-02
<b>STAGE</b>			
<b>Stage IA</b>	(n=12)	(n=12) <sup>b</sup>	
CDKN2A EX2	182.57	47.28	4.9E-04
CDX2	99.71	3.15	4.9E-04
HOXA1	143.06	3.25	1.0E-03
OPCML	189.43	7.65	4.9E-04
<b>Stage IB</b>	(n=6)	(n=6) <sup>b</sup>	
CDKN2A EX2	190.67	61.00	3.1E-02
CDX2	20.62	13.36	<b>3.1E-01</b>
HOXA1	78.98	2.15	6.3E-02
OPCML	76.62	15.16	6.3E-02
<b>Stage IIA/IIB/IIIA<sup>c</sup></b>	(n=10)	(n=10) <sup>b</sup>	
CDKN2A EX2	208.05	39.81	1.0E-02
CDX2	83.22	1.78	2.0E-03
HOXA1	180.18	6.16	2.0E-03
OPCML	178.54	8.25	2.0E-03

<sup>a</sup> p-value calculated by mann-whitney for gender and race and wilcoxon signed rank test for stage, in which paired adjacent non-tumor samples were used.

<sup>b</sup> For stage comparisons, paired adjacent samples from same patients as tumors were used.

<sup>c</sup> Only one paired sample was available for stages IIA and IIIA and none for IIB, hence IIA/IIB/IIIA were pooled.